<DOC>
	<DOC>NCT02656797</DOC>
	<brief_summary>Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis of Leishmania species major and tropica.</brief_summary>
	<brief_title>Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis</brief_title>
	<detailed_description>Randomized, double blind, placebo controlled study. The study will include 108 patients with cutenous leishmaniasis of Leishmania species major and tropica, confired by Polymerase Chain Reaction of a sample from a lesion. Cure rate will be compared between patients treated with Amphotericin-B 0.4% Liposomal Gel and patients treated with placebo gel preparation.</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis, Cutaneous</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Cutenous leishmaniasis confirmed by PCR (Leishmania species major or tropica) 1 to 5 lesions Signed informed consent Facial lesions Significant comorbidity Pregnancy or breastfeeding at enrollment Previous treatment for leishmaniasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Leishmania major</keyword>
	<keyword>Leishmania tropica</keyword>
	<keyword>Amphotericin B</keyword>
</DOC>